Sharp Invests $20 Million in Autoinjector & Pen Assembly Lines to Meet Rising Demand for Injectables

Sharp Services, a leader in pharmaceutical packaging, clinical trial services & sterile manufacturing, has announced a $20 million investment in its autoinjector and pen assembly, labeling and packaging lines across various therapeutic areas at its facility in Macungie, PA.

The announcement follows recent market reports that have predicted the autoinjector market is projected to reach $20.6 billion globally by 2030, with a CAGR of 15.1%, due in part to convenience and usability for both patients and healthcare providers.

Sharp’s Macungie facility will boast two autoinjector assembly lines to support both clinical and commercial needs. Investments include a low-speed semi-manual, 2 devices per minute line, to support the assembly of custom and non-custom pens and autoinjectors. The second line will offer mid-speed assembly of 50-70 devices per minute with inline labeling and cartoning, and will support both Ypsomed’s YpsoMate® and SHL Medical’s Molly® autoinjectors.

Jeff Benedict, Chief Commercial Officer of Sharp, commented: “Pharma organizations are increasingly choosing injectables in advanced delivery systems that ensure reliable and safe drug administration, especially in critical or emergency scenarios. The rapid rise in demand for obesity management products, coupled with the market requirement for more sustainable solutions, has fueled innovation and unlocked new possibilities in this space.”

Autoinjectors and pens assembled, labeled and packaged at Sharp will be used for a wide range of emergency, chronic, and specialty conditions. The new production lines in Macungie that will support the specific requirements of these devices and therapies are expected to be fully operational in the first half of 2027.

Benedict continued: “Following the successful implementation of our assembly capabilities at our Hamont-Achel facility in Belgium, our new production lines in the US will position Sharp to support the global market. Sharp’s expertise in autoinjector packaging, combined with our experience of the global market, makes this an exciting opportunity for our existing and new clients.”

With a network of nine GMP facilities across the US, UK and Europe, Sharp has a deep knowledge and breadth of expertise to support clients with integrated sterile manufacturing, clinical trial services and commercial packaging solutions.

Discover more about its services here.

Sharp is a leader in commercial packaging, clinical services & sterile manufacturing. For 70+ years, we’ve provided solutions to pharma and biotech clients from phase I trials through to commercial launch and lifecycle management. With facilities in the United States, United Kingdom, Belgium & the Netherlands and 30+ clinical depots globally, covering every region of the world, our experience is your strength.

Our full complement of integrated services includes research and development, clinical manufacturing, sterile development and fill/finish services, primary and secondary packaging of both investigational and commercial product, package design, serialization and aggregation, storage, distribution and clinical IRT. Sharp also offers Qualified Person (QP) services to meet the complex regulatory demands of drug product release in the EU and UK. = For more information on Sharp and its solutions, visit www.sharpservices.com or follow us on LinkedIn.